Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 73

Sort by

Sort Order Select

Journal Articles

ULK1 Presents As a Therapeutic Target to Sensitize Resistant Acute Myeloid Leukemia Cells to Venetoclax

Heather Betz, Xiaoyan Jiang

Blood (2024) 144 (Supplement 1): 2776.

https://doi.org/10.1182/blood-2024-206028

Published: 2024

Journal Articles

Restoration of Mir-185 in Combination with BCR-ABL Downregulation By Therapeutic Delivery of siRNA with Lipid Nanoparticle Carriers Targets Drug Resistant Leukemic Stem/Progenitor Cells

Athena Phoa, Min Chen, Xiaoyan Jiang

Blood (2023) 142 (Supplement 1): 1424.

https://doi.org/10.1182/blood-2023-175044

Published: 2023

Journal Articles

Identification of Multivariable microRNA and Clinical Biomarkers Panels to Predict Imatinib Response in Chronic Myeloid Leukemia at Diagnosis

Andrew Wu, Ryan Yen, Sarah Grasedieck, Hanyang Lin, Helen Nakamoto, Donna L. Forrest, Connie J. Eaves, Xiaoyan Jiang

Blood (2023) 142 (Supplement 1): 4547.

https://doi.org/10.1182/blood-2023-180252

Published: 2023

Journal Articles

Targeting Abnormally Increased Expression of ULK1 Sensitizes Acute Myeloid Leukemia Resistant Cells to Venetoclax

Heather Betz, Xiaoyan Jiang

Blood (2023) 142 (Supplement 1): 5740.

https://doi.org/10.1182/blood-2023-178856

Published: 2023

Journal Articles

Targeting a Highly Deregulated eIF4F Translation Initiation Complex Sensitises IM-Resistant Cells to Tyrosine Kinase Inhibitors and Effectively Suppresses BCR-ABL1 Protein Expression

Ryan Yen, Lambert Yue, Steven Pelech, Xiaoyan Jiang

Blood (2022) 140 (Supplement 1): 3864.

https://doi.org/10.1182/blood-2022-167088

Published: 2022

Journal Articles

Identification of Key microRNAs As Predictive Biomarkers of Nilotinib Response in Chronic Myeloid Leukemia: A Sub-Analysis of the Enestxtnd Clinical Trial

Andrew Wu, Ryan Yen, Sarah Grasedieck, Hanyang Lin, Jiechuang Su, Katharina Rothe, Helen Nakamoto, Donna L. Forrest, Connie J. Eaves, Xiaoyan Jiang

Blood (2022) 140 (Supplement 1): 12169–12170.

https://doi.org/10.1182/blood-2022-168534

Published: 2022

Journal Articles

Implementing RNAi Therapy Targeting FLT3 in Acute Myeloid Leukemia (AML)

Aysha Ansari, Remant Bahadur KC, Mohammad Nasrullah, Daniel NM Sundaram, Luis Morales Burbano, Joseph Brandwein, Xiaoyan Jiang, Hasan Uludag

Blood (2022) 140 (Supplement 1): 7791–7792.

https://doi.org/10.1182/blood-2022-169187

Published: 2022

Journal Articles

Newly Developed Oncolytic Herpes Simplex Viruses Expressing Multiple Immunomodulatory Transgenes Effectively Target AML Cells

Yixin Zheng, Min Chen, Yanal Murad, Luke Bu, William Jia, Xiaoyan Jiang

Blood (2021) 138 (Supplement 1): 1169.

https://doi.org/10.1182/blood-2021-150965

Published: 2021

Journal Articles

Identification of a Highly Deregulated eIF4F Translation Initiation Complex in Drug-Resistant BCR-ABL + Cells By a Phospho-Proteomic Antibody Microarray

Ryan Yen, Lambert Yue, Steven Pelech, Xiaoyan Jiang

Blood (2021) 138 (Supplement 1): 3583.

https://doi.org/10.1182/blood-2021-149185

Published: 2021

Journal Articles

Targeting AXL kinase sensitizes leukemic stem and progenitor cells to venetoclax treatment in acute myeloid leukemia

Blood (2021) 137 (26): 3641–3655.

https://doi.org/10.1182/blood.2020007651

Published: 2021

Includes: Supplemental data

Journal Articles

Targeting AXL Kinase Sensitizes Acute Myeloid Leukemia Stem and Progenitor Cells to Venetoclax Treatment

Katharina Rothe, PhD, Xiaojia Niu, PhD, Min Chen, PhD, Rick Li, Sungeun Nam, Xiuyan Zhang, German Novakovskiy, Yehyeon Ahn, Shenshen Lai, Hong Zhang, PhD, Jun Yan, Hong Liu, Yun Zhao, PhD, Depei Wu, MDPhD, Yubin Ge, PhD, Wyeth W. Wasserman, Calvin K. Yip, Zaihui Zhang, PhD, Xiaoyan Jiang, MD PhD

Blood (2020) 136 (Supplement 1): 20.

https://doi.org/10.1182/blood-2020-140595

Published: 2020

Journal Articles

Inhibition of PAK6-Mediated Survival and Cell Cycle Controls Selectively Targets Therapy-Resistant CML Stem/Progenitor Cells

Andrew Wu, BSc, Min Chen, PhD, Ryan Yen, BSc, Xiaoyan Jiang, MD PhD

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-140459

Published: 2020

Journal Articles

The miR-185/PAK6 axis predicts therapy response and regulates survival of drug-resistant leukemic stem cells in CML

Blood (2020) 136 (5): 596–609.

https://doi.org/10.1182/blood.2019003636

Published: 2020

Includes: Supplemental data

Journal Articles

The AHI-1-BCR-ABL-DNM2 Complex Mediates Mitochondrial Dynamics in Drug-Resistant BCR-ABL + Cells

Ryan Yen, BSc, Lambert Yue, BSc, Steven Pelech, PhD, Xiaoyan Jiang, MD PhD

Blood (2019) 134 (Supplement_1): 189.

https://doi.org/10.1182/blood-2019-128712

Published: 2019

Journal Articles

Inhibition of the MiR-185-PAK6-Mediated Survival and Metabolic Pathways Selectively Targets Drug-Resistant CML Stem/Progenitor Cells

Andrew Wu, BSc, Katharina Rothe, PhD, Min Chen, PhD, Hanyang Lin, PhD, Artem Babaian, PhD, Ryan Yen, BSc, Donna L. Forrest, MD, Xiaoyan Jiang, MD PhD

Blood (2019) 134 (Supplement_1): 4138.

https://doi.org/10.1182/blood-2019-127826

Published: 2019

Journal Articles

Global Transcriptome Profiling Identifies a Key Mir-185-PAK6 Axis That Promotes Survival of Leukemic Stem Cells and Drug-Insensitive Blasts in BCR-ABL + Human Leukemia

Andrew Wu, BSc, Lin Hanyang, PhD, Katharina Rothe, PhD, Min Chen, MD PhD, Jens Ruschmann, PhD, Oleh Petriv, PhD, Kieran O'Neill, PhD, Tobias Maetzig, MD, David Knapp, PhD, Naoto Nakamichi, MD PhD, Ryan Brinkman, PhD, Inanc Birol, PhD, Donna L Forrest, MD, Carl Hansen, PhD, R. Keith Humphries, MD PhD, Connie J. Eaves, PhD, Xiaoyan Jiang, MD PhD

Blood (2018) 132 (Supplement 1): 931.

https://doi.org/10.1182/blood-2018-99-113559

Published: 2018

Journal Articles

Inhibiting the Core Autophagy Enzyme ATG4B with Novel Drugs Sensitizes Resistant Leukemic Stem/Progenitor Cells to Standard Targeted Therapy

Katharina Rothe, PhD, Akie Watanabe, Donna L. Forrest, MD, Sharon Gorski, PhD, Robert Young, PhD, Xiaoyan Jiang, MDPhD

Blood (2018) 132 (Supplement 1): 933.

https://doi.org/10.1182/blood-2018-99-117309

Published: 2018

Journal Articles

Loss of Ahi-1 Impairs the Self-Renewal Activity of Normal and BCR-ABL + Stem Cells in Vitro and in Vivo

Min Chen, Kevin Lin, PhD, Xiaoyan Jiang, MD PhD

Blood (2017) 130 (Supplement 1): 2516.

https://doi.org/10.1182/blood.V130.Suppl_1.2516.2516

Published: 2017

Journal Articles

Targeting the GAS6/AXL Pathway with a Newly Developed AXL-Selective Inhibitor SLC-0211 for the Treatment of Acute Myeloid Leukemia

Xiaojia Niu, Katharina Roche, PhD, Min Chen, MD PhD, Hong Zhang, PhD, Jun Yan, Yubin Ge, PhD, Zaihui Zhang, PhD, Xiaoyan Jiang, MD PhD

Blood (2017) 130 (Supplement 1): 2640.

https://doi.org/10.1182/blood.V130.Suppl_1.2640.2640

Published: 2017

Journal Articles

Drug-Insensitive CML Stem/Progenitor Cells Highly Express Key Regulators of the Hedgehog Pathway and Inhibition of the Hedgehog Pathway Enhances Their Response to TKI Treatment

Kelly A. Turner, BSc, Katharina Rothe, PhD, Adrian Woolfson, MD PhD, Xiaoyan Jiang, MD PhD

Blood (2016) 128 (22): 4236.

https://doi.org/10.1182/blood.V128.22.4236.4236

Published: 2016

NARROW

ULK1 Presents As a Therapeutic Target to Sensitize Resistant Acute Myeloid Leukemia Cells to Venetoclax

Restoration of Mir-185 in Combination with BCR-ABL Downregulation By Therapeutic Delivery of siRNA with Lipid Nanoparticle Carriers Targets Drug Resistant Leukemic Stem/Progenitor Cells

Identification of Multivariable microRNA and Clinical Biomarkers Panels to Predict Imatinib Response in Chronic Myeloid Leukemia at Diagnosis

Targeting Abnormally Increased Expression of ULK1 Sensitizes Acute Myeloid Leukemia Resistant Cells to Venetoclax

Targeting a Highly Deregulated eIF4F Translation Initiation Complex Sensitises IM-Resistant Cells to Tyrosine Kinase Inhibitors and Effectively Suppresses BCR-ABL1 Protein Expression

Identification of Key microRNAs As Predictive Biomarkers of Nilotinib Response in Chronic Myeloid Leukemia: A Sub-Analysis of the Enestxtnd Clinical Trial

Implementing RNAi Therapy Targeting FLT3 in Acute Myeloid Leukemia (AML)

Newly Developed Oncolytic Herpes Simplex Viruses Expressing Multiple Immunomodulatory Transgenes Effectively Target AML Cells

Identification of a Highly Deregulated eIF4F Translation Initiation Complex in Drug-Resistant BCR-ABL + Cells By a Phospho-Proteomic Antibody Microarray

Targeting AXL kinase sensitizes leukemic stem and progenitor cells to venetoclax treatment in acute myeloid leukemia

Targeting AXL Kinase Sensitizes Acute Myeloid Leukemia Stem and Progenitor Cells to Venetoclax Treatment

Inhibition of PAK6-Mediated Survival and Cell Cycle Controls Selectively Targets Therapy-Resistant CML Stem/Progenitor Cells

The miR-185/PAK6 axis predicts therapy response and regulates survival of drug-resistant leukemic stem cells in CML

The AHI-1-BCR-ABL-DNM2 Complex Mediates Mitochondrial Dynamics in Drug-Resistant BCR-ABL + Cells

Inhibition of the MiR-185-PAK6-Mediated Survival and Metabolic Pathways Selectively Targets Drug-Resistant CML Stem/Progenitor Cells

Global Transcriptome Profiling Identifies a Key Mir-185-PAK6 Axis That Promotes Survival of Leukemic Stem Cells and Drug-Insensitive Blasts in BCR-ABL + Human Leukemia

Inhibiting the Core Autophagy Enzyme ATG4B with Novel Drugs Sensitizes Resistant Leukemic Stem/Progenitor Cells to Standard Targeted Therapy

Loss of Ahi-1 Impairs the Self-Renewal Activity of Normal and BCR-ABL + Stem Cells in Vitro and in Vivo

Targeting the GAS6/AXL Pathway with a Newly Developed AXL-Selective Inhibitor SLC-0211 for the Treatment of Acute Myeloid Leukemia

Drug-Insensitive CML Stem/Progenitor Cells Highly Express Key Regulators of the Hedgehog Pathway and Inhibition of the Hedgehog Pathway Enhances Their Response to TKI Treatment

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only